Dainippon Sumitomo, Takeda deal

Takeda granted Dainippon exclusive rights to develop and commercialize ceftaroline ( TAK-599) in Japan. Takeda will receive Y500 million ($6 million) up front and is eligible for up to Y2.5 billion ($29.8 million) in developmental milestones. Takeda will be eligible for undisclosed commercial milestones and royalties. Dainippon is responsible for funding development and commercialization of the cephalosporin antibiotic. Dainippon said it plans to develop ceftaroline to treat hospital-acquired bacterial pneumonia, sepsis and other methicillin-resistant Staphylococcus aureus (MRSA) infections. ...